Actinogen Medical Alzheimer's Trial Completes Last Patient Visit
Key points
- XanaMIA Alzheimer's trial completes final patient visit
- Topline results expected in November 2026
- Trial focuses on elevated cortisol levels in the brain
Full summary
Actinogen Medical Ltd announced that the XanaMIA phase 2b/3 Alzheimer's disease (AD) clinical trial has completed the final patient visit, confirming that topline results remain on track for November. The trial, which enrolled 247 participants in Australia and the US, focuses on Xanamem, an oral enzyme inhibitor designed to control elevated cortisol levels in the brain. The trial is a randomized, double-blind, placebo-controlled study comparing Xanamem 10 mg to placebo over 36 weeks, with an open-label extension phase for all participants.
Outlook
The Company plans to finalize high-quality data from the XanaMIA pivotal trial for release in November and streamline pathways for regulatory approvals.
Summary generated by a large language model. Please interpret with care.